bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.11.09.687528

Annotation-Free Prediction of Cancer Cells and Glands and Spatial Analysis of Immune Cells.

Abstract

Prostate cancer is classified as "immune-cold" due to limited infiltration of immune cells and no clear correlation between immune cells and clinical outcomes. However, immune cells are found in prostate cancers and the spatial relationships between these immune cells and cancer cells/glands have not been investigated, partly due to a lack of automated tools that classify both cancerous cells/glands. In this paper, we have developed an end-to-end tool (TOPAZ: Tissue Organization identification using sPAtial proteomics) that combines multiplexed single-cell protein data with histology images to: 1) predict cancerous versus non-cancerous epithelial cells using a Gaussian-mixture model; 2) predict cancerous/non-cancerous gland type using a principal curve estimation. Using TOPAZ to assign cancer and non-cancerous labels to cells and glands, we extracted multiscale spatial features from the classification results--including immune dense-region geometrical features and cell-to-gland distances-- and correlated the features with risk of biochemical recurrence and cancer grade. Tissue-microarrays containing 753 cores from 217 prostate cancer patients underwent multiplexed immunofluorescent imaging (Cell DIVE, Leica) for epithelial cell markers (panCK26, S6, NaKATPase), basal cell markers (p63, CK5), a cancer cell marker (AMACR), and T cell markers (CD3, CD4, CD8, FOXP3, CD68). Cancerous/non-cancerous cell classification from TOPAZ achieved 82% sensitivity and 99% specificity against expert annotation, and the pipeline further predicted cancerous/non-cancerous glands without manual threshold tuning. Regulatory-T-cell and helper-T-cell percentages decreased, and macrophage percentage increased with grade increase (P < 0.05). When the median distance from cancerous gland centroids to the nearest regulatory or helper T-cell exceeded approximately 50 {micro}m, the hazard of biochemical recurrence doubled (log-rank P < 0.01). The open-source Shiny app TOPAZ (https://chunglab.bmi.osumc.edu/TOPAZ) packages the workflow, predicting individual cell types and gland shapes. By combining probabilistic cell typing with gland-shape modeling, TOPAZ yields interpretable multiscale spatial features linked to prognosis and is released as an open web app for unrestricted use. Author SummarySpatial distribution of cancerous cells/glands and immune cell distribution has not been considered as a prognosticator in prostate cancer. In addition, automated tools that can quantify and integrate these distributions are lacking. We combined high-dimensional single-cell protein measurements with histology images to map gland structure in prostate cancer tissue. Our web-based tool, TOPAZ (https://chunglab.bmi.osumc.edu/TOPAZ) predicts whether each epithelial cell and gland in virtual H&E image is cancerous or not. Once the predictions are made, a spatial analysis workflow helps quantify spatial features of immune cells relative to the glands and correlate with recurrence risk and grades. Across 753 tissue cores from 217 prostate cancer patients, helper and regulatory-T-cells located more than about 50 {micro}m away from cancerous epithelial glands were associated with a higher risk of biochemical recurrence. The pipeline provides new insights for researchers and pathologists into prostate cancer progression and biochemical recurrence through integration of spatial location of cancer glands and immune cells.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jung, K. J., Ghose, S., Cho, S., McDonough, E., Chadwick, C., West, R., Brooks, J. D., Chung, D., Ginty, F., Machiraju, R., Mallick, P.. 2025-11-10. Annotation-Free Prediction of Cancer Cells and Glands and Spatial Analysis of Immune Cells.. https://doi.org/10.1101/2025.11.09.687528

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

m6A-Driven Intratumoral Cholesterol Biosynthesis Fuels Castration-Resistant Prostate Cancer Progression

Both nuclear pore complexes (NPCs) and RNA N6-methyladenosine (m6A) machinery are indispensable for proper cellular function. Although their collaborative roles in the nuclear export of messenger RNAs (mRNAs) have been reported, it remains ambiguous whether and how this collaboration may contribute to cancer progression. Here we identify a functional cooperation between NPCs and m6A signaling that promotes the development of castration-resistant prostate cancer (CRPC). We showed that nuclear export of m6A-modified mRNAs, mediated by the interaction between RNA methyltransferase METTL3 and the nucleoporin NUP93, is functionally coupled to cholesterol biosynthesis. Given that cholesterol-fueled intratumoral androgen production is one of the mechanisms driving CRPC, we demonstrated that overexpression of the wild-type METTL3 or NUP93, but neither the enzymatically dead METTL3 nor the mutant NUP93 that loses METTL3-interacting capability, elevates intracellular levels of androgens, activates AR signaling under castrate condition, and promotes androgen-independent growth of prostate cancer cells both in vitro and in vivo. Importantly, pharmacological inhibition of METTL3 or targeted demethylation on mRNAs encoding key cholesterol biosynthesis enzymes effectively suppressed CRPC malignancy. Together, these findings uncover a therapeutically targetable m6A-METTL3-NUP93 axis that links nuclear mRNA export and metabolic reprogramming to fuel CRPC progression, providing a conceptually new strategy for the treatment of this lethal disease.

cancer biology↗

ST6Gal2 promotes α2,6-sialylation and aggressive phenotypes in neuroblastoma cells

Neuroblastoma is the most common extracranial solid tumor of childhood. Its clinical behavior ranges from spontaneous regression to lethal, treatment-refractory disease. Aberrant 2,6-sialylation contributes to aggressive phenotypes in many cancers, but the role of ST6Gal2, a neural-enriched 2,6-sialyltransferase, in neuroblastoma is largely unexplored. Here, we examine the clinical and functional significance of ST6Gal2 in neuroblastoma. In two independent public cohorts (SEQC, n=498; Kocak, n=649), high ST6GAL2 expression was associated with significantly worse overall and event-free survival. In the SEQC cohort, ST6GAL2 expression was higher in high-risk and MYCN-amplified tumors, varied across International Neuroblastoma Staging System stages, and correlated positively with a mesenchymal transcriptional signature (Spearman {rho}=0.181). The mesenchymal correlation was reproduced in the Kocak cohort ({rho}=0.204). Stable shRNA-mediated knockdown of ST6GAL2 in SK-N-AS and SK-N-BE(2) cells reduced proliferation and viability, impaired wound closure, and decreased migration and invasion. In preliminary experiments in SK-N-AS cells, ST6GAL2 knockdown reduced binding of Sambucus nigra agglutinin, consistent with a role for ST6Gal2 in 2,6-sialylation. Together, these findings link ST6Gal2 expression to aggressive clinical and transcriptional features and pro-tumorigenic phenotypes in neuroblastoma and nominate ST6Gal2-mediated sialylation as a candidate pathway for mechanistic study.

cancer biology↗

Unsupervised transcriptomic analysis of paired pre- and post-treatment specimens reveals divergent chemoimmunomodulatory induction trajectories in breast cancer

The immunomodulatory effects of chemotherapy (chemoimmunomodulation; CIM) are clinically consequential and heterogeneous, yet no systematic framework exists for classifying the immunomodulatory trajectory a tumor follows in response to treatment (CIM trajectory). Here, we present the CIM Induction Classifier (CIMIC), an unsupervised clustering pipeline leveraging delta gene expression across 3,189 CIM-related genes to classify specimens chemoimmunomodulatory trajectory. Applied to two pre- and post-chemotherapy breast cancer (BC) datasets (NKI/SMC, N = 36; NEO, N = 19) and nine epirubicin-perturbed triple-negative BC (TNBC) cell lines, CIMIC identified two divergent CIM trajectories: a functional CIM (Fun-CIM) trajectory, broadly conserved across tumors and cell lines and characterized by induction of inflammatory cell death, antigen presentation, viral mimicry, and adaptive immune activation programs, and a dysfunctional CIM (Dys-CIM) trajectory, characterized by induction of proteostatic and metabolic stress-adaptation programs, reduced immune cell abundances and cytotoxic activity, and enrichment of aggressive BC subtypes. Using survival and longitudinal transcriptomic data in NKI/SMC (N = 20), treatment-induced increases in Fun-CIM-associated genes and ssGSEA scores were associated with reduced recurrence, whereas Dys-CIM-associated genes and scores were associated with increased recurrence. In multivariable analyses within independent chemotherapy-treated BC cohorts (METABRIC, N = 412; SCAN-B, N = 2,462), higher baseline Fun-CIM ssGSEA scores were associated with better outcomes, whereas higher baseline Dys-CIM ssGSEA scores were associated with worse outcomes. These findings establish CIM as a dynamic, trajectory-level process and position CIMIC as a framework for defining CIM trajectories and supporting future efforts to identify predictors, mechanisms, and therapeutic strategies that maximize beneficial CIM.

cancer biology↗